Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in ...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

The global gene therapy market is projected to grow at a significant CAGR of 20% from 2024 to 2029. This growth is driven by ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amgen (AMGN) one of those stocks right now? A quick glance at ...

A phenotype-based profiling test can help predict whether a patient might respond better to one antiobesity medicine or ...

Ghana is witnessing a sharp increase in oncology or cancer incidences with approximately 27,385 new cases reported in 2022 ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mereo Biopharma Group Plc (MREO – Research Report), Amgen (AMGN – Research Rep ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: ...